News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biohit Signs Distribution Ageement With Xediton


12/28/2012 9:01:17 AM

Finnish healthcare company Biohit Oyj has signed a distribution agreement with Canadian Xediton Pharmaceuticals Inc. The agreement covers the distribution and marketing of Biohit product Acetium in Canada.

Acetium is unique and patented product to bind carcinogenic acetaldehyde. The agreement gives Xediton exclusive rights to distribute Acetium products in its market area. Acetium is intended e.g. for persons suffering from atrophic gastritis caused by Helicobacter pylori infection or autoimmune disease. An anacidic stomach is the most significant risk factor in stomach and oesophageal cancer. The risk group includes approximately 500 million people globally

Read at GlobeNewswire

comments powered by Disqus
Biohit
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES